BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17404485)

  • 1. [Inhibition of the joint destruction in RA by TNF-blocking agents].
    Kameda H
    Clin Calcium; 2007 Apr; 17(4):553-60. PubMed ID: 17404485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of the inhibition of joint destruction in RA by TNF-blocking agents].
    Nagasawa H; Takeuchi T
    Clin Calcium; 2009 Mar; 19(3):416-24. PubMed ID: 19252252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Daily practice using the guidelines for prevention and treatment of osteoporosis. The effects of anti-TNF therapy on bone and joint manifestations in rheumatoid arthritis].
    Soen S
    Clin Calcium; 2008 Aug; 18(8):1169-75. PubMed ID: 18677056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
    Segal B; Rhodus NL; Patel K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological agents for therapy of rheumatoid arthritis--overview].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
    [No Abstract]   [Full Text] [Related]  

  • 7. Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?
    O'Dell JR
    N Engl J Med; 1999 Jan; 340(4):310-2. PubMed ID: 9920958
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)].
    Akiyama Y; Mimura T
    Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.
    Tutuncu Z; Kavanaugh A; Zvaifler N; Corr M; Deutsch R; Boyle D
    Arthritis Rheum; 2005 Sep; 52(9):2693-6. PubMed ID: 16142749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
    Baker DE
    Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Paradigm shift in the treatment of rheumatoid arthritis by biologics].
    Tanaka Y
    Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biological agents targeting on pro-inflammatory cytokines].
    Takeuchi T
    Nihon Rinsho; 2005 Sep; 63(9):1601-6. PubMed ID: 16164218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL; Kingsley GH
    N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 18. Rheumatoid arthritis.
    Burchini G; Orsi C
    N Engl J Med; 2004 Sep; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
    [No Abstract]   [Full Text] [Related]  

  • 19. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
    Yamaguchi Y; Yamamoto K
    Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis].
    Finckh A; Gabay C; Guerne PA
    Rev Med Suisse Romande; 2004 Sep; 124(9):547-50. PubMed ID: 15552748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.